Analysts Set Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Target Price at $18.75

Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the seven analysts that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, three have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $18.75.

ATRA has been the topic of several analyst reports. TD Cowen raised Atara Biotherapeutics to a "strong-buy" rating in a research report on Friday, November 29th. Rodman & Renshaw began coverage on shares of Atara Biotherapeutics in a research note on Friday, December 20th. They issued a "buy" rating and a $25.00 target price for the company. Canaccord Genuity Group raised their price target on shares of Atara Biotherapeutics from $13.00 to $21.00 and gave the company a "buy" rating in a research report on Wednesday, November 13th. Finally, RODMAN&RENSHAW raised shares of Atara Biotherapeutics to a "strong-buy" rating in a research report on Friday, December 20th.

Atara Biotherapeutics Stock Performance

Atara Biotherapeutics stock traded down $1.15 during mid-day trading on Tuesday, reaching $16.85. The stock had a trading volume of 170,772 shares, compared to its average volume of 234,468. Atara Biotherapeutics has a fifty-two week low of $6.50 and a fifty-two week high of $39.50. The stock's 50-day simple moving average is $12.06 and its 200-day simple moving average is $9.73. The firm has a market capitalization of $97.06 million, a PE ratio of -0.65 and a beta of 0.51.

Atara Biotherapeutics (NASDAQ:ATRA - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($2.93) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($3.77) by $0.84. The business had revenue of $40.19 million for the quarter, compared to analyst estimates of $23.00 million. During the same quarter in the prior year, the business earned ($16.50) earnings per share. On average, research analysts forecast that Atara Biotherapeutics will post -12.12 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Atara Biotherapeutics

A number of hedge funds have recently modified their holdings of ATRA. State Street Corp increased its stake in shares of Atara Biotherapeutics by 52.3% in the third quarter. State Street Corp now owns 22,353 shares of the biotechnology company's stock worth $182,000 after purchasing an additional 7,680 shares in the last quarter. FMR LLC grew its stake in Atara Biotherapeutics by 41.7% in the 3rd quarter. FMR LLC now owns 25,061 shares of the biotechnology company's stock valued at $204,000 after buying an additional 7,381 shares in the last quarter. Cubist Systematic Strategies LLC bought a new stake in Atara Biotherapeutics during the 2nd quarter valued at $79,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Atara Biotherapeutics during the second quarter worth $53,000. Finally, Vestal Point Capital LP boosted its holdings in shares of Atara Biotherapeutics by 11.3% in the third quarter. Vestal Point Capital LP now owns 124,677 shares of the biotechnology company's stock worth $1,014,000 after acquiring an additional 12,677 shares during the period. Institutional investors own 70.90% of the company's stock.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.